<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370798</url>
  </required_header>
  <id_info>
    <org_study_id>2010.608</org_study_id>
    <secondary_id>2010-023686-22</secondary_id>
    <nct_id>NCT01370798</nct_id>
  </id_info>
  <brief_title>Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications</brief_title>
  <acronym>HYPOSPADES</acronym>
  <official_title>Local Oestrogen Versus Placebo as Preoperative Treatment in Patients With Severe Hypospadias: Effects on Post-operative Complications.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypospadias is a congenital abnormality of the penis that is caused by incomplete development
      of the anterior urethra. This pathology is one of the most common genital anomalies in
      paediatric urology .The incidence is reported to be 1 out of 250 live male births and is
      increasing regularly. The hypospadias surgeries present a high risk of post operative
      complications requiring re-interventions.

      A great part of the post operative complications is related to imperfect healing issues. If
      androgen stimulation seems to be deleterious, at the opposite, oestrogen could impact
      positively on the skin healing process. This point leads to the hypothesis that local
      transcutaneous oestrogen stimulation on the ventral and dorsal penile faces decreases the
      number of skin healing post-operative defects.

      The objective of the study is to assess the effect of oestrogen (applied once daily for 2
      months prior to surgery) on the post-operative complications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 26, 2011</start_date>
  <completion_date type="Actual">September 18, 2017</completion_date>
  <primary_completion_date type="Actual">September 18, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patient with postoperative urethral fistula and dehiscence</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Re-intervention related to wound healing</measure>
    <time_frame>1 year</time_frame>
    <description>Number of re-interventions for fistula or dehiscence not related to stenosis, in the first year post surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-surgical complications</measure>
    <time_frame>1 year</time_frame>
    <description>Total number and type of post-surgical complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-intervention not related to wound healing</measure>
    <time_frame>1 year</time_frame>
    <description>Number of re-interventions not related to wound healing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone measurement</measure>
    <time_frame>2 months</time_frame>
    <description>Plasmatic concentrations of Oestradiol, Testosterone, LH, FSH at inclusion and at 2 months (at the end of study treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone age evaluation</measure>
    <time_frame>14 monthes</time_frame>
    <description>Hand and wrist radiography at inclusion and 1 year after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical tolerance of the treatment</measure>
    <time_frame>14 months</time_frame>
    <description>Number and type of adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Hypospadias</condition>
  <arm_group>
    <arm_group_label>promestriene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children with severe hypospadias treated with promestriene 1%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control group, children with severe hypospadias treated with Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>promestriene</intervention_name>
    <description>Promestriene cream 1%, 1g per day during 2 months, cutaneous application</description>
    <arm_group_label>promestriene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of promestriene cream, 1g per day during 2 months, cutaneous application</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urethroplasty</intervention_name>
    <description>Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)</description>
    <arm_group_label>promestriene</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Wrist X ray</intervention_name>
    <description>Wrist X ray to follow the degree of bone maturation</description>
    <arm_group_label>promestriene</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH</description>
    <arm_group_label>promestriene</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe hypospadias with a division of the corpus spongiosum behind the midshaft of the
             penis and for which repair requires a urethral substitution by onlay urethroplasty.

          -  Subjects operated between 9 and 36 months old.

          -  Subjects operated in one of the departments of paediatric urology involved in the
             study.

          -  Surgery performed by a surgeon with at least 5 years of practical experience in the
             hypospadias surgery.

          -  Written informed consent obtained from parents or legal guardians prior to the
             participation to the study

          -  All hypospadias aetiology (hormonal, karyotype or genetic)

        Exclusion Criteria:

          -  Refusal to participate

          -  Subjects with glandular hypospadias

          -  Subjects aged &lt;9 months or &gt; 36months old at time of surgery.

          -  Subjects who had prior surgery of penis (circumcision or hypospadias surgery)

          -  Subjects treated with androgens (Human Chorionic Gonadotrophin or delayed
             testosterone) within 6 months prior to surgery.

          -  Intolerance to promestriene or its excipients.

          -  Not affiliated to a healthy or social security cover.

          -  Known tumoral risk

          -  Pure or mixed gonadal dysgenesis (45, X0/46,XY)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Mouriquand, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL FEMME MERE ENFANT CHU DE LYON</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Chirurgie Pédiatrique Uro-génitale, Hopital femme Mere Enfant</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Mère-Enfant</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>72015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital NECKER</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe hypospadias</keyword>
  <keyword>local oestrogen</keyword>
  <keyword>promestriene</keyword>
  <keyword>Onlay-tube-onlay urethroplasty</keyword>
  <keyword>post-operative complications</keyword>
  <keyword>fistula dehiscence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypospadias</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

